Answer
The injected formulation is a ready-to-use abdominal subcutaneous solution containing hyaluronidase. The intravenous concentrate must be diluted and infused. Their licensed indications are not identical, and administration reactions were less frequent with the subcutaneous formulation in comparative studies.
Sources for this answer
- DARZALEX 1,800 mg solution for injectionemc · SmPC Current selected SmPC · Version 25
- DARZALEX 20 mg/mL concentrate for solution for infusion